In This Issue
Journal: Cancer Discovery (2022)

In This Issue| December 02 2022 In This Issue Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2022 American Association for Cancer Research2022American Association for Cancer Research Cancer Discov (2022) 12 (12): 2711–2713. https://doi.org/10.1158/2159-8290.CD-12-12-ITI Related Content A commentary has been published: Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes A commentary has been published: Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4 A commentary has been published: BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma View more A commentary has been published: Distinct Tumor Necrosis Factor Alpha Receptors Dictate Stem Cell Fitness versus Lineage Output in Dnmt3a-Mutant Clonal Hematopoiesis A commentary has been published: Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis A commentary has been published: Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma A commentary has been published: Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma A commentary has been published: Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer A commentary has been published: Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture A commentary has been published: Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record December 2 2022 Citation In This Issue. Cancer Discov 1 December 2022; 12 (12): 2711–2713. https://doi.org/10.1158/2159-8290.CD-12-12-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Jerusalem and colleagues evaluated trastuzumab deruxtecan (T-DXd) in subgroups of HER2-positive metastatic breast cancer in patients with (n = 24) and without (n = 160) a history of brain metastases (BM) from DESTINY-Breast01, confirming objective response rate and median progression-free survival were 58.3% and 18.1 months and 61.3% and 16.4 months, respectively, consistent with the primary analysis. Eight patients (47.1%) experienced a best overall intracranial response of partial or complete response, and seven patients (41.2%) had a best percentage change from baseline in brain lesion diameter consistent with stable disease. Durable clinical activity of T-DXd in patients with BMs was promising and necessitates continued investigation. See article, p. 2754. An understanding of the mechanisms that promote selective advantage and abnormal myeloid cell production in clonal hematopoiesis (CH) is critical in the development of therapies to reduce the risk of myeloid malignancies, cardiovascular disease, and other associated conditions. Here,... You do not currently have access to this content.